Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | GSK3A | P49840 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293317 | 0.84 | KMT2A (0.73) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL29234520 | 0.82 | GSK3A (0.69) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL7263122 | 0.82 | GSK3A (0.69) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL5311390 | 0.82 | GSK3A (0.69) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL11090828 | 0.82 | GSK3A (0.59) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL3318940 | 0.81 | GSK3A (1.00) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL6407514 | 0.81 | MEN1 (0.64) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL30953279 | 0.80 | GSK3A (0.71) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL378362 | 0.79 | GSK3A (0.65) | SMN1; SMN2GAAGSK3AGSK3BKMT2A | |
| SCHEMBL4455461 | 0.79 | GSK3A (0.69) | SMN1; SMN2GAAGSK3AGSK3BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-10-13 | — | — | US | disclosed |
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-21 | — | — | US | disclosed |
| EP-3768670-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | Aurigene Discovery Technologies Limited (IN) | 2021-01-27 | — | — | EP | disclosed |
| US-20210002299-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-01-07 | — | — | US | disclosed |
| WO-2019180628-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-09-26 | — | — | WO | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | PRMT5, PRMT1, PRMT7 | SMN1; SMN2 1783/4885GAA 4223/4885GSK3A 2409/4885 |
| US-20210002299-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | PRMT5, PRMT1, PRMT7 | SMN1; SMN2 1783/4885GAA 4223/4885GSK3A 2409/4885 |
| US-20220324878-A1 | IMIDAZOLIDIN-2-ONE COMPOUNDS AS PRMT5 MODULATORS | PRMT5, PRMT1, PRMT7 | SMN1; SMN2 1783/4885GAA 4223/4885GSK3A 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.